IBA, Elekta partner on particle therapy

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Ion Beam Applications (IBA) and Elekta today revealed a global particle therapy collaboration program at the American Society for Therapeutic Radiology and Oncology meeting in Los Angeles. The program was created to optimize the integration of proton therapy delivery and information management systems within the radiation oncology environment.

Under terms of the agreement, IBA and Elekta will provide particle therapy packages to meet specific clinical requirements. On the Elekta side, this can include its Mosaiq workflow management and oncology information system, Mosaiq proton therapy module, patient immobilization devices, localization systems, and its Synergy advanced intensity modulated radiation therapy and image-guided radiation therapy delivery system.

On the IBA side, the agreement includes its Proteus proton therapy system. More components may be added in the future based on customer requirements, the firms noted.
The collaboration will also include joint development of future integrated product offerings for proton therapy. Complementing the development agreement, the two companies will also join forces in sales and marketing for the particle therapy solutions.
“The IBA proton therapy solution is intrinsically open to interface with any radiation therapy system. However, as cancer centers expect the oncology information System  software and other radiation therapy equipment to operate seamlessly and intelligently with the proton therapy system, the IBA and Elekta joint development will make the proton therapy system a benchmark of integration,” said Pierre Mottet, IBA’s CEO.

“We have been able to quickly find common ground, both technically and commercially,” said Tomas Puusepp, president and CEO of Elekta.